Telehealth affiliate and creator programs: what can be paid for, and what cannot

A telehealth affiliate program looks like any other affiliate program until the payout terms are written down. A skincare brand can pay a creator ten dollars for every order their link produces and nobody objects. A brand whose order is a prescription cannot, in most states, without walking into fee-splitting and patient-brokering rules that were written to stop exactly that payment. The rule that keeps the program on the right side is short: pay creators for audience, not for prescriptions. Per-click, per-view and flat fees for content are compensation for marketing. A bounty that pays when a provider writes a prescription is a payment for a patient, and the fact that it is routed through an affiliate platform does not change what it is.

What a brand can pay a creator for

Marketing is a service, and a brand can buy it at a fair price. The structures below pay for the work of reaching an audience and are the ones counsel in most states will accept without much discussion.

• A flat fee for a defined deliverable: a video, a series of posts, a newsletter placement, a podcast read. The fee is set in advance and does not move with what happens after.
• A per-click or per-view fee, where the brand pays for traffic delivered to its site and the creator's earnings depend on the size and engagement of their audience, not on what visitors do once they arrive.
• A retainer for an ongoing relationship, with content quotas, exclusivity and usage rights, priced on the creator's reach.
• A licensing fee for using the creator's content in the brand's own ads, priced separately from the posting fee.
• A per-lead fee where a lead is defined as something that happens before any clinical contact, such as an account created or a quiz completed, at a modest fixed amount that reflects the marketing value of a lead rather than the revenue value of a patient, and only after counsel has reviewed it against the states involved.

What a brand cannot pay for

The payment to avoid is any amount that is triggered by, or scales with, a prescription being written, a consultation being completed, or a treatment subscription starting. That includes the obvious per-prescription bounty and the less obvious versions: a percentage of first-month revenue, a tiered bonus that unlocks when a creator's referrals convert to paying patients, or a per-lead fee where the lead is defined as a completed consult.

Three bodies of law reach these payments. The federal Anti-Kickback Statute applies only where a federal healthcare program pays for something, so a cash-pay telehealth brand is usually outside it, and operators sometimes stop there. The state rules do not stop there. Most states have a fee-splitting rule in their medical practice act that bars a physician from sharing professional fees with someone who referred the patient, and several states have patient-brokering statutes that make it an offense to pay or receive anything of value for referring a patient to a provider, regardless of who pays for the treatment. The definitions vary, the penalties in some states are criminal, and the person who wrote the check is as exposed as the person who cashed it. The brief for this post did not verify any single state's statute, so none is cited here; the state pages cover where each state's rules land, and the payment structure should be reviewed in every state the creator's audience is likely to come from, which for a national creator is all of them.

There is also a practical reason beyond the law. A creator paid per prescription has an incentive to tell their audience they will get one. That claim is false, because the provider decides, and it is the single fastest way for a brand to draw a consumer-protection complaint and a platform ban. A creator paid for audience has no reason to promise anything.

Pay creators for the audience they bring. The moment a payment moves with whether a provider wrote a prescription, it has become a payment for a patient, whatever the affiliate dashboard calls it.

What the FTC requires creators to disclose

The FTC's Endorsement Guides apply to every paid or gifted relationship between a brand and someone who talks about it, and the FTC's published guidance on them is direct about the test: "if there's a connection between an endorser and the marketer that a significant minority of consumers wouldn't expect and it would affect how they evaluate the endorsement, that connection should be disclosed clearly and conspicuously." A fee, a free product, an affiliate commission and an employment relationship all count. Affiliate links specifically require disclosure, and the FTC's example language is "I get commissions for purchases made through links in this post."

Clear and conspicuous has a meaning. For video, the FTC says a disclosure should be "presented simultaneously in both the visual and audible portions" of the content, and it should come early rather than in end credits. A simple "#ad" works; a hashtag that buries the word in something else does not, and the FTC's own example of a failure is a tag where "consumers won't notice and understand the significance of the word 'ad' at the end." Disclosures below the fold, behind a "more" link or only in a profile bio do not meet the standard. The guidance's placement rule is that "the disclosure should catch users' attention and be placed where they aren't likely to miss it."

Two more points from the same guidance matter for health brands. An endorser must actually have used the product: "You can't talk about your experience with a product if you haven't tried it," and "If you thought it was terrible or mediocre, you can't say it's good or terrific." And the brand is on the hook for what its endorsers say. The FTC states that "Advertisers need to have reasonable programs in place to train and monitor members of their network," that the brand should "periodically search for what members of your network are saying," and that "Your company is ultimately responsible for what others do on your behalf." A creator agreement that mentions disclosure once and is never enforced is not a reasonable program.

Keeping creator claims inside the lines

Health claims are where creator programs generate the most regulatory exposure, because the creator is speaking in their own voice about their own body and the brand is liable for it. A creator who says a program helped them lose a specific number of pounds in a specific number of weeks has made a results claim on the brand's behalf, and it needs the same substantiation the brand would need in its own ad. A creator who says a compounded product is "the same as" a brand-name drug has made a claim the FDA has been sending letters about. A creator who says viewers will get a prescription has made a false claim about a medical decision they do not control.

The controls that work are unglamorous. Give every creator a written brief that lists the claims they may make and the claims they may not, in plain language, with examples of each. Require a script or an outline for anything about results, side effects or medication, and review it before it goes live. Provide the disclosure wording and require it in the first few seconds of video and the first line of a caption. Monitor published content on a schedule and keep a log of what was checked. Reserve the right to pull content and end the relationship, and use it once so that the rest of the roster knows it is real. The weight-loss marketing claims guide lists the specific claim patterns that draw enforcement in the largest vertical, and the same list, adjusted for the condition, works for hormone, hair and sexual-health creators.

The brand pays, the medical practice does not

In a white-label telehealth structure there are two entities, and it matters which one signs the creator agreement. The professional corporation, the friendly PC that employs the providers and holds the patient relationship, is the entity that fee-splitting and patient-brokering rules are written around. It should have no contract with any creator, pay no marketing commissions, and receive no revenue that flows from a creator's referral other than its ordinary professional fees. The management services organization, the MSO that owns the brand and buys the practice's non-clinical services, is a marketing business among other things, and it is the entity that contracts with creators, pays them from its own funds for marketing services at fair market value, and reports the payments.

That split is not a trick. It works because the MSO's payment to a creator does not depend on clinical outcomes, and the practice's income does not depend on the creator. If the MSO pays the creator per prescription, the split stops protecting anyone, because the payment is still a payment for a patient and the practice's professional fee is still what funds it. For creator programs the operational rule is that the practice is invisible to the affiliate platform and the affiliate platform never sees a clinical event.

How the brand itself pays its platform provider has a similar shape. A flat fee versus revenue share arrangement between a brand and the company running its clinical operations raises the same fee-splitting questions as a creator commission, which is one reason Tessic Health charges a flat $25 per completed consult with no revenue share on any plan. The economics of a creator program are easier to model on top of a flat per-consult cost, since the brand knows what a patient costs to serve before it decides what an audience is worth.

Tracking creators without sending health data

An affiliate program runs on attribution, and attribution in a telehealth brand collides with the health-data restrictions the ad platforms and the state privacy laws now impose. The creator's link carries a code; the brand needs to know that a visitor with that code did something; the creator wants a dashboard. Each of those steps can leak health information if it is built the default way.

Keep the link code and the landing path free of condition words. A creator link that resolves to /glp1?ref=creatorname tells every intermediary, including the affiliate platform and any pixel on the page, what the visitor is there for. A neutral landing path with the creator code stored in a first-party cookie or session on the brand's own domain carries the attribution without the diagnosis.

Count conversions in the brand's own system, on the storefront side, at the event the payout is based on, which under the structures above is a click, a view, an account or a quiz completion, never a consultation or a prescription. Report to the affiliate platform, and to the creator's dashboard, only the count and the payout. The platform does not need the visitor's email, the program chosen or whether the person became a patient, and the brand should not have a data flow that could send it. If the brand also runs Meta or Google pixels, the same event design that keeps those pixels clean keeps the affiliate tracking clean: standard events, no parameters that name a condition, and the practice's clinical system nowhere near the pipeline.

Creators who run their own paid ads for the brand are a separate case, because Google requires the advertiser of prescription-drug ads to be certified and a creator's ad account is not the brand's certified account. Most brands keep creators to organic content and run any paid use of creator content from the brand's own certified account.

Questions operators ask

Can the brand pay a creator a percentage of subscription revenue for the non-prescription part of the program, such as coaching or a supplement bundle? Revenue share on a product that has nothing to do with the prescription is the ordinary affiliate case. The trouble comes when the non-prescription product is bundled with the treatment so that the share moves with treatment revenue in practice, which is the outcome the fee-splitting rules look at. If the share only ever exists for a product sold without a consultation, it is cleaner; if it is a way of paying for the prescription by another name, it is not.

Can a creator be a patient of the practice and also a paid endorser? Yes, and many are. The brand should not condition the fee on the creator continuing treatment, should not have access to the creator's clinical records, and should treat what the creator says about their own results as a claim to review like any other. The practice treats the creator as a patient and nothing else.

Do referral bonuses for existing patients raise the same issue? A give-twenty-get-twenty program where a patient's friend gets a discount and the patient gets account credit is a payment for a referral, and in states with patient-brokering statutes it can fall inside them even at small amounts. Some brands run them, structured as a discount on non-prescription items or as credit that does not depend on the friend receiving a prescription. It is a state-by-state question and one to put to counsel before launching.

What does a creator who wants to launch their own brand need to know? The rules in this post are the ones they will be on the other side of. A creator-founded telehealth brand pays other creators under the same constraints, and the creators page lays out how the structure, the practice and the pharmacy work for a founder whose main asset is an audience.